公开(公告)号：US20230346934A1

公开(公告)日：2023-11-02

申请号：US18191955

申请日：2023-03-29

Applicant: Allogene Therapeutics, Inc.

Inventor： Yi ZHANG ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU ,  Siler PANOWSKI ,  Regina Junhui LIN ,  Zhe LI

IPC: A61K39/00 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  C07K16/22 ,  C07K14/725 ,  A61P35/00

CPC classification number: A61K39/4611 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2827 ,  C07K16/22 ,  C07K14/70507 ,  C07K14/70517 ,  C07K14/7051 ,  A61K39/4631 ,  A61K39/4643 ,  A61P35/00 ,  C07K2319/03 ,  C07K2317/622 ,  C07K2319/02 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/23 ,  A61K2239/28

Abstract: Provided herein are chimeric switch receptors (CSRs) comprising an ectodomain and/or transmembrane domain derived from an inhibitory receptor (e.g. PD1 or TGFβR2) fused to the transmembrane domain and/or intracellular signaling domain derived from one or more costimulatory proteins (e.g. CD2, CD28, MyD88, DAP10 or ICOS), or variants thereof. The chimeric switch receptors are designed to convert a signal e.g. an inhibitory signal such as an immunosuppressive signal in the form of PD-L1 or TGFβ into a costimulatory signal. Also provided are engineered immune cells engineered to functionally express a chimeric switch receptor and/or a CAR and optionally also a chimeric cytokine receptor (CCR), and populations thereof, methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating e.g. cancer (e.g. solid or hematologic tumors) by administering the cells and the compositions.

公开(公告)号：US20240042030A1

公开(公告)日：2024-02-08

申请号：US18361056

申请日：2023-07-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Cesar Adolfo SOMMER ,  Hsin-Yuan CHENG ,  Barbra Johnson SASU

IPC: A61K39/00 ,  C12N15/113 ,  C12N5/0783 ,  A61P35/00

CPC classification number: A61K39/4631 ,  C12N15/113 ,  A61K39/4613 ,  C12N5/0646 ,  A61P35/00 ,  C12N2510/00

Abstract: Provided herein are engineered immune cells and populations thereof for administration to subjects to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of CD48, CD58, ICAM-1, RFX5, NLRC5, TAP2, β2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) and/or a CD70 binding protein to target tumor cells or other damaged cells in the subject and/or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions.

公开(公告)号：US20240003056A1

公开(公告)日：2024-01-04

申请号：US18354037

申请日：2023-07-18

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles PERTEL ,  Barbra Johnson SASU

IPC: C40B40/10 ,  C07K16/40 ,  C12N15/63

CPC classification number: C40B40/10 ,  C07K16/40 ,  C12N15/63 ,  C07K2317/565

Abstract: The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.

公开(公告)号：US20210260118A1

公开(公告)日：2021-08-26

申请号：US17183689

申请日：2021-02-24

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Siler PANOWSKI ,  Cesar Adolfo SOMMER ,  Thomas John VAN BLARCOM ,  Barbra Johnson SASU ,  Arun BALAKUMARAN

IPC: A61K35/17 ,  C07K14/715 ,  C07K16/28 ,  C12N15/86 ,  A61P35/00

Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.

公开(公告)号：US20210061881A1

公开(公告)日：2021-03-04

申请号：US17005757

申请日：2020-08-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Siler PANOWSKI ,  Thomas John VAN BLARCOM ,  Shanshan LANG ,  Barbra Johnson SASU

IPC: C07K14/71 ,  C12N15/86 ,  C12N5/0783 ,  A61K35/17

Abstract: Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-β ligand or a TGF-β receptor antibody. When present on chimeric antigen receptor (CAR)-bearing immune cells (CAR-T-cells), such receptors allow for increased CAR-T cell expansion, activity and persistence, constitutively and/or through engagement of a TGF-β ligand or a TGF-β receptor antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

公开(公告)号：US20250051421A1

公开(公告)日：2025-02-13

申请号：US18741447

申请日：2024-06-12

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: C07K14/715 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/86

Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.

公开(公告)号：US20240277763A1

公开(公告)日：2024-08-22

申请号：US18395996

申请日：2023-12-26

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles PERTEL ,  Barbra Johnson SASU ,  Mark W. LEONARD

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/33 ,  C12N2510/00 ,  C12N2740/15043

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically birnds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

公开(公告)号：US20230407252A1

公开(公告)日：2023-12-21

申请号：US18308797

申请日：2023-04-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Meng-Yin LIN ,  Hayung YOON ,  Thomas Charles PERTEL ,  Barbra Johnson SASU

IPC: C12N5/0783 ,  C07K14/725

CPC classification number: C12N5/0636 ,  C07K14/7051 ,  C12N2510/00 ,  C07K2319/03 ,  C07K2319/02

Abstract: Provided herein are methods, kits and reagents for analyzing the attributes of cell populations, such as donor cells prior to modification to provide engineered cells, e.g., engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of biomarkers and/or secretion profiles of donor cell populations, selecting donor cells with certain biomarkers and/or secretion profiles, and engineering the CAR T cells from the selected donor cells.

公开(公告)号：US20200331998A1

公开(公告)日：2020-10-22

申请号：US16851691

申请日：2020-04-17

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles PERTEL ,  Barbra Johnson SASU ,  Tao SAI

IPC: C07K16/28 ,  A61K35/17

Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.

公开(公告)号：US20200291090A1

公开(公告)日：2020-09-17

申请号：US16804917

申请日：2020-02-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: C07K14/715 ,  C07K16/40 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/86 ,  A61K35/17 ,  A61P35/00

Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.